Hepatic Clinical Trials in San Antonio, Texas
21 recruitingSan Antonio, Texas
Showing 1–20 of 21 trials
Recruiting
Phase 1
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
Healthy VolunteersHepatic Impairment
Bristol-Myers Squibb24 enrolled3 locationsNCT07248839
Recruiting
Phase 1
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Phase 1
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Hepatic Insufficiency
Eli Lilly and Company36 enrolled3 locationsNCT07401862
Recruiting
Phase 1
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Phase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 2
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 2
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
Hepatic CirrhosisLiver Fibrosis
AstraZeneca104 enrolled19 locationsNCT07610837
Recruiting
Phase 1
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Moderate Hepatic Impairment
AstraZeneca20 enrolled2 locationsNCT07343960
Recruiting
Phase 1
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim44 enrolled1 locationNCT07486102
Recruiting
Phase 1
Radiprodil in Participants With Hepatic Impairment
Hepatic Impairment
GRIN Therapeutics, Inc.40 enrolled2 locationsNCT07457229
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
HealthyHepatic Impairment
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany32 enrolled3 locationsNCT06997276
Recruiting
Phase 1
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
Hepatic Insufficiency
Boehringer Ingelheim44 enrolled3 locationsNCT06957756
Recruiting
Phase 1Phase 2
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Colorectal, CancerUrothelial CarcinomaSquamous Non-small-cell Lung Cancer+2 more
Alentis Therapeutics AG180 enrolled28 locationsNCT07169734
Recruiting
Phase 1
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
HealthyHepatic Impairment
Merck Sharp & Dohme LLC58 enrolled3 locationsNCT07219550
Recruiting
Phase 1
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Hepatic Impairment (HI)
Merck Sharp & Dohme LLC32 enrolled3 locationsNCT06442436
Recruiting
Phase 1
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
Cirrhosis, LiverLiver FibrosisAscites Hepatic
PharmaIN74 enrolled9 locationsNCT05490888
Recruiting
Phase 1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Moderate Hepatic ImpairmentHepatic Impairment
Exelixis20 enrolled2 locationsNCT06962332
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
CirrhosisHepatic Impairment
Vir Biotechnology, Inc.144 enrolled5 locationsNCT05484206
Recruiting
Phase 1
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Hepatic Insufficiency
X4 Pharmaceuticals48 enrolled4 locationsNCT06858696